Preeclampsia prevention strategies. Pharmacokinetics and pharmacodynamics of low-molecular-weight heparin (LMWH) in pregnancy

N. Ţurcan, R. Bohîlțea, D. Ioniță, A. Baroş, E. Radu, L. Arsene, F. Păuleț, M.M. Cîrstoiu

Rezumat: Preeclampsia is a disease characteristic only to human pregnancy, birth being its only healing method. The morbidity and mortality associated with this condition are considerable, therefore therapies aimed at preventing the development of preeclampsia, which could delay the onset of the disease or decrease its severity, are essential. Pregnant women with an increased risk of thromboembolic disease require anticoagulant treatment throughout pregnancy. The effects and pharmacokinetics of the anticoagulant treatment used are mandatory to be known, given that in some cases the teratogenic effect may be present and in all cases the adaptation of the treatment near and during labor must be individualized. The low-molecular-weight heparin (LMWH) response is more predictable than unfractionated heparin, and in the context of adverse effects and unlikely overdose, routine monitoring by biological tests is not required. For each patient undergoing anticoagulant treatment during pregnancy for the purpose of preventing thrombotic injury, there should be explained the signs and symptoms of thrombosis, taking into account the fact that, even though the thrombotic risk is very low under anticoagulant treatment, a degree of risk still persists in pregnancy. Preeclampsia risk assessment project aims to gather all the data regarding the personal and familial history, obsterical and clinical data that impact the risk of developing a hypertensive pathology in pregnancy.
Cuvinte cheie: preeclampsia, anticoagulant, prevention.